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Abstract
The insulin-like growth factor receptor I (IGF-IR) plays an essential role in transformation by promoting cell growth and
protecting cancer cells from apoptosis. We have recently demonstrated that the IGF-IR is overexpressed in invasive bladder
cancer tissues and promotes motility and invasion of urothelial carcinoma cells. These effects require IGF-I-induced Akt- and
MAPK-dependent activation of paxillin. The latter co-localizes with focal adhesion kinases (FAK) at dynamic focal adhesions
and is critical for promoting motility of urothelial cancer cells. FAK and its homolog Proline-rich tyrosine kinase 2 (Pyk2)
modulate paxillin activation; however, their role in regulating IGF-IR-dependent signaling and motility in bladder cancer has
not been established. In this study we demonstrate that FAK was not required for IGF-IR-dependent signaling and motility
of invasive urothelial carcinoma cells. On the contrary, Pyk2, which was strongly activated by IGF-I, was critical for IGF-IR-
dependent motility and invasion and regulated IGF-I-dependent activation of the Akt and MAPK pathways. Using
immunofluorescence and AQUA analysis we further discovered that Pyk2 was overexpressed in bladder cancer tissues as
compared to normal tissue controls. Significantly, in urothelial carcinoma tissues there was increased Pyk2 localization in the
nuclei as compared to normal tissue controls. These results provide the first evidence of a specific Pyk2 activity in regulating
IGF-IR-dependent motility and invasion of bladder cancer cells suggesting that Pyk2 and the IGF-IR may play a critical role in
the invasive phenotype in urothelial neoplasia. In addition, Pyk2 and the IGF-IR may serve as novel biomarkers with
diagnostic and prognostic significance in bladder cancer.
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Introduction
Bladder cancer is a major epidemiological problem, whose
incidence continues to rise. The most recent cancer statistic has
estimated 73,510 new cases and 14,880 estimated deaths in the
United States for 2012 [1]. The majority of bladder tumors
(,70%) are low-grade noninvasive papillary tumors that do not
penetrate the epithelial basement membrane (Ta stage). The
remainder comprise tumors that have penetrated the basement
membrane but not invaded the muscle layer of the bladder wall
(T1 stage) and muscle-invasive tumors (T2, T3 and T4 stages)
[2,3,4]. The prognosis for low-grade tumors is generally good, but
about 10%–15% of these patients will later develop invasive
disease. For invasive tumors the prognosis is much less favorable,
with only 50% survival at 5 years. Invasive tumors frequently
progress to life-threatening metastases, which is associated with a 5
year survival rate of 6% [3,4]. Thus, understanding the
mechanisms that regulate bladder tumor invasion is critical to
predict and treat this devastating condition in bladder cancer
patients.
It is well established that the insulin-like growth factor
receptor I (IGF-IR) plays a critical role in cell growth both in
vitro [5] and in vivo [6]. Mice with targeted ablation of the IGF-
IR gene have severe growth retardation, being only 45% the
size of wild-type littermates [7,8]. Studies performed in mouse
embryo fibroblasts derived from the IGF-IR-deficient mice (R-
cells) have really underscored the essential role of the IGF-IR in
transformation [9]. R-cells are indeed refractory to trans-
formation induced by several tumorigenic agents (viral onco-
genes such as Ras and SV40 large T Ag, as well as over-
expressed PDGFR and EGFR, and various chemical agents) but
are transformed upon IGF-IR re-expression [10,11]. Experi-
ments on tumor cell lines and epidemiological studies have
confirmed that activation of the IGF-IR is involved in the
development of many common neoplastic diseases, including
carcinomas of lung, prostate, pancreas, liver, colon and breast
[10,12,13]. The transforming capability of the IGF-IR most
likely depends on its ability to protect cancer cells from
apoptosis [11,12,14,15,16].
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We have recently demonstrated that the IGF-IR is upregulated
in invasive and high-grade bladder cancer tumor tissues compared
to low-grade and normal tissue controls and promotes motility and
invasion of urothelial cancer cells [17,18]. Significantly, IGF-IR
activation did not induce cell proliferation of bladder cancer cells,
indicating that the IGF-IR acts as a ‘‘scatter factor’’ for urothelial
carcinoma-derived cells and may regulate the transition to the
invasive stage of bladder cancer [17]. We also showed that IGF-
IR-dependent cell motility and invasion required the activation of
the Akt and MAPK pathway [17,18] and Akt- and ERK-
dependent activation of paxillin, which upon IGF-I-stimulation
colocalized with focal adhesion kinase (FAK) in dynamic adhesions
at the leading edge of migrating urothelial cancer cells and was
critical for IGF-I-induced motility of these cells [17].
Here we show that while FAK was not required for IGF-IR-
dependent signaling and motility of invasive urothelial carcinoma
cells, the FAK-related Pyk2 [19,20] was strongly activated by IGF-
I in urothelial carcinoma cells, was critical for IGF-IR-dependent
motility and invasion and regulated IGF-I-dependent activation of
the Akt and MAPK pathways. We also discovered that Pyk2 is
overexpressed in bladder cancer tissues compared to normal tissue
controls and that there is a striking increase in Pyk2 translocation
to the nuclei of these malignant cells.
Collectively, these results provide novel information toward
a better understanding of the mechanisms that regulate tumor
progression in bladder cancer and suggest that Pyk2 and the IGF-
IR may be critical for the transition to the invasive phenotype. In
addition, these studies could potentially contribute to the
identification of novel targets for therapeutic intervention in
bladder tumors.
Results
FAK Activity in the Regulation of IGF-I-induced Migration,
Invasion and Signaling
We recently discovered that paxillin plays an important role in
regulating IGF-IR-dependent motility of urothelial carcinomas
[17]. It is well established that FAK regulates paxillin activation
[21] and the assembly/disassembly of focal adhesions (adhesion
turnover) at the cell front of migrating cells [22]. However, it is
not yet established whether FAK or its homolog Pyk2 [19,20],
which is also expressed by urothelial cancer cells, may play a role
in regulating IGF-I-induced motility of bladder cancer cells. Thus,
we first employed small interfering RNA (siRNA) strategies to
transiently deplete endogenous FAK in 5637 invasive urothelial
carcinoma cells and then assessed FAK function in the regulation
of IGF-I-induced motility and invasion. We reached a very
significant depletion of endogenous FAK with the anti-FAK
siRNA (Figure 1A). The oligos were specific for FAK insofar as
there was no effect on Pyk2 expression levels (Figure 1A). Notably,
FAK depletion did not induce a statistically-significant decrease in
IGF-I-mediated migratory response in 5637 cells compared to
either parental or scrambled oligos-transfected cells (Figure 1B).
However, the invasive ability of 5637 cells was reduced, although
at levels barely below statistical significance (P= 0.046) as
compared to control oligos-transfected cells (Figure 1C). In
addition, using immunoblot analysis with phospho-specific anti-
bodies, we discovered that FAK depletion did not affect IGF-I-
mediated activation of the MAPK or Akt pathways (Figure 1D),
which are both necessary for IGF-IR-dependent motility and
invasion of urothelial cancer cells [17,18].
Collectively, these results do not support a critical role for FAK
in regulating IGF-IR-dependent motility and invasive capability of
urothelial cancer cells.
Pyk2 is Critical for IGF-I-induced Motility, Invasion and
Signaling
It is known that Pyk2 can promote both distinct and over-
lapping signaling events with FAK [23,24]. As we could not
establish a major role for FAK in IGF-I-evoked motility of
urothelial cancer cells, we considered the alternate hypothesis that
Pyk2 is a predominant intracellular kinase that could mediate the
downstream signaling pathway triggered by activation of the IGF-
IR in urothelial cancer cells.
First, we discovered that IGF-I stimulation of 5637 cells induced
a prolonged Pyk2 activation, which was sustained for up to 2
hours, as determined by immunoblot with anti-Phospho-Pyk2
antibody (Figure 2A). Second, we performed transient transfection
assays in 5637 cells and determined that overexpression of wild
type Pyk2 significantly increased IGF-I-induced migration, which
was inhibited by the expression of a kinase-dead dominant
negative Pyk2 (**P,0.01, compared to V-transfected cells)
(Figure 2B). Proper expression of Flag-tagged wild-type or
kinase-dead Pyk2 proteins was determined by immunoblot with
anti-Flag antibodies (Figure 2C).
Next, to confirm Pyk2 function, we depleted endogenous Pyk2
in 5637 cells by siRNA approaches. Pyk2 depletion (Figure 3A)
severely inhibited IGF-I-induced tumor cell migration (Figure 3B)
and invasion through MatrigelTM (Figure 3C). Interestingly, Pyk2
depletion slightly upregulated FAK levels (Figure 3A), although
FAK was unable to compensate for Pyk2 loss. In addition, Pyk2
knockdown in 5637 cells affected IGF-IR-downstream signaling
and inhibited IGF-I-dependent activation of Akt and ERK1/2
and downstream effectors S6K and p90RSK (Figure 3D).
To corroborate our results on Pyk2 function, we transiently
depleted by siRNA approaches endogenous Pyk2 in T24 cells,
another IGF-I-responsive invasive urothelial cancer cell line
[17,18]. We achieved a significant reduction in Pyk2 levels (Figure
S1A) with a concurrent reduction in the ability of T24 cells to
migrate (Figure S1B) and invade (Figure S1C) in response to IGF-I
stimulation (*P,0.05, compared to either mock transfected or
control oligo-transfected cells). In addition, Pyk2 ablation in T24
cells was associated with reduced IGF-I-dependent activation of
ERK1/2 and S6K, while Akt and p90RSK activation was not
affected (Figure S1D).
Collectively, our findings reveal an essential role for Pyk2 in the
IGF-IR functional regulation of tumor cell motility and invasion,
key properties of the aggressive cancer phenotype.
Pyk2 colocalizes with the IGF-IR and Complexes with IRS-
1/2 and Grb2 in Urothelial Cancer Cells
To determine whether Pyk2 may interact with the IGF-IR in
5637 cells, we initially performed co-immunoprecipitation assays
but we were unable to detect an interaction between endogenous
IGF-IR and Pyk2 proteins. Thus, we used confocal microscopy
analysis to determine whether Pyk2 may colocalize with the IGF-
IR in 5637 urothelial cancer cells. While in serum-starved 5637
cells Pyk2 did not colocalize with the IGF-IR (Figure 4A), 30
minutes of IGF-I stimulation induced significant colocalization of
endogenous Pyk2 and IGF-IR proteins (Figure 4A) suggesting that
Pyk2 may be recruited to the IGF-IR upon ligand stimulation.
Next, to investigate the mechanisms by which Pyk2 regulates
IGF-IR downstream signaling, we performed co-immunoprecip-
itation assays in both 5637 and T24 cells. The main goal of these
studies was to determine whether Pyk2 would complex with the
docking proteins IRS-1 and/or IRS-2 or Grb2 adaptors, known to
regulate IGF-IR-dependent activation of the Akt and MAPK
pathways, respectively [25,26,27]. In 5637 cells, IRS-1 was
Pyk2 and IGF-IR in Bladder Cancer
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Figure 1. FAK is not important for IGF-I-mediated motility and signaling of invasive urothelial cancer cells. (A) 5637 cells were
transfected with the FAK siGenome pool or control oligos. After 72 hours FAK and Pyk2 expression was detected by immunoblot with specific
antibodies. Blot is representative of three independent experiments with an average FAK depletion level of 93.363.5 (arbitrary units) as assessed by
densitometric analysis (B and C) Migration and invasion assays of 5637 cells were performed as described in Materials and Methods and assessed after
16 hours of IGF-I stimulation. Values are expressed as fold change over SFM and represent mean 6 SD. *P= 0.046. (D) FAK-depleted 5637 cells were
tested for Akt and MAPK activation after 10 minutes of IGF-I stimulation using a mix of phospho-specific antibodies (PathScan Cocktail I). eIF4E
monitors protein loads. Blot is representative of three independent experiments.
doi:10.1371/journal.pone.0040148.g001
Figure 2. IGF-I-activated Pyk2 is critical for IGF-IR-dependent motility of invasive urothelial cancer cells. (A) Serum-starved 5637 cells
were stimulated with 50 ng/ml of IGF-I for the indicated time points. Pyk2 phosphorylation was detected by immunoblot using anti-phospho-Pyk2
(Tyr402) antibodies, while total Pyk2 protein level was assessed using anti-Pyk2 polyclonal antibodies. Blot is representative of two independent
experiments. (B) Migration of 5637 cells transiently transfected with either Flag-tagged wild type (PYK2 WT) or a dominant negative (KD PYK2) Pyk2
proteins was assessed after 16 hours of IGF-I stimulation. Values are expressed as fold change over SFM and represent mean 6 SD. ** P,0.01. (C)
Expression levels of transiently transfected Pyk2 proteins were assessed by immunoblot with anti-flag M2 antibodies. Blot is representative of two
independent experiments.
doi:10.1371/journal.pone.0040148.g002
Pyk2 and IGF-IR in Bladder Cancer
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detectable in complex with Pyk2 in unstimulated cells but
uncoupled from Pyk2 after 30 minutes of IGF-I stimulation
(Figure 4B). In contrast, IRS-2 binding to Pyk2 was barely
detectable in serum-starved 5637 cells but strongly increased after
IGF-I stimulation (Figure 4B). Grb2 recruitment to Pyk2 was
detectable in unstimulated 5637 cells but it was strongly enhanced
after ligand stimulation (Figure 4B). The same results were
recapitulated in T24 cells with only some differences in the levels
of IRS-1, IRS-2 and Grb2 detectable in Pyk2 co-immunopreci-
pitates (Figure 4C). These qualitative differences may be likely due
to differences in the relative abundance of these proteins in 5637
and T24 cells as in fact 5637 cells express higher level of Pyk2
proteins compared to T4 (data not shown). In addition, the
interaction between Pyk2, IRS-1 and IRS-2 could be indirect and
mediated by additional associated proteins, which may differ
between 5637 and T24 cells.
These results indicate that Pyk2, by recruiting IRS-2 and Grb2,
could play a critical role in regulating IGF-IR-dependent
activation of downstream signaling pathways required for motility
and invasion of urothelial cancer cells.
Pyk2 is Overexpressed in Bladder Cancer Tissues
We have recently shown that the IGF-IR is overexpressed in
invasive bladder cancer tissues compared to normal tissue controls
[17] and IGF-IR levels increase with bladder cancer progression
[18]. Thus, we determined the expression of Pyk2 in a well
annotated bladder cancer tissue microarray using immunofluores-
cence and AQUA analysis (Automated Quantitative Analysis)
[28]. Pyk2 expression significantly increased in various bladder
cancer tissues types (Figure 5A and B) as compared to normal
tissue controls. In addition, the AQUA analysis for Pyk2
expression in various cellular compartments revealed that there
was a significantly higher level of Pyk2 expression in the nuclei of
urothelial cancer tissue cells when compared to cells in normal
tissues (*P=0.012, Figure 5C).
Nuclear Pyk2 staining is better visualized at higher magnifica-
tion of selected field of normal and urothelial carcinoma tissues
(Figure S2).
Collectively, our results have identified a novel protein in the
IGF-IR pathway that may be critical for bladder cancer. They also
provide the first evidence that Pyk2 may translocate into the nuclei
of bladder cancer cells. In addition, Pyk2 may serve in conjunction
with the IGF-IR as a novel diagnostic and possibly prognostic
biomarker for bladder cancer.
Discussion
The molecular mechanisms that determine malignant trans-
formation of urothelial cells in the bladder are still very poorly
characterized. In addition, there is an urgent need to identify
proteins that may play a key role in driving the progression to the
invasive and possibly metastatic phenotype in bladder neoplasia
[2,3,4].
We have recently established that activation of the IGF-IR does
not evoke in vitro cell proliferation but promotes motility and
invasion of urothelial cancer cells [17,18]. These results support
the hypothesis that the IGF-IR may not be so critical for bladder
cancer initiation, but may play a prominent role during pro-
gression to the invasive and possibly metastatic stage of bladder
cancer.
Based on our previous observation that upon IGF-I-stimulation
FAK localizes with paxillin at dynamic adhesion sites of migrating
cells [17], we investigated whether FAK, or its homolog Pyk2,
would modulate IGF-IR action in urothelial cancer cells. We
demonstrate that: (i) Depletion of endogenous FAK protein by
siRNA strategies does not affect IGF-I-dependent motility and
signaling of 5637 urothelial cancer cells. (ii) The FAK homolog
Pyk2 is activated upon IGF-I stimulation of 5637 cells. (iii)
Transient expression of wild type Pyk2 enhances IGF-I-induced
migration, which is severely inhibited instead by the expression of
a dominant-negative kinase-dead Pyk2 mutant. (iv) Pyk2 depletion
by siRNA approaches inhibits IGF-I-dependent migration and
invasive ability of 5637 and T24 cells and affects IGF-IR
downstream signaling. (v) Upon IGF-I stimulation Pyk2 complex
with IRS-2 and Grb2 in 5637 and T24 urothelial cancer cells. (vi)
Pyk2 is overexpressed in various bladder cancer tissue types
compared to normal tissue controls. (vii) Pyk2 expression
increases in the nuclei of urothelial cancer tissue cells compared
to normal tissue cells.
FAK and Pyk2 are related tyrosine-kinases involved in the
dynamic regulation of the actin cytoskeleton, a process critical for
cell motility, mitosis and tumor progression [24,29]. FAK and
Pyk2 share a conserved molecular architecture and exhibit an
overall 45% sequence identity with the greatest sequence identity
(60%) in the kinase domain [24,29]. FAK is ubiquitously expressed
while Pyk2 expression has a more limited tissue distribution with
the highest Pyk2 expression levels detected in cells of the central
nervous system and in hematopoietic lineage [29]. In addition,
FAK and Pyk2 differs for their intracellular distribution, with FAK
Figure 3. Pyk2 is critical for IGF-IR-induced motility, invasion and signaling of invasive urothelial cancer cells. (A) 5637 cells were
transfected with the Pyk2 siGenome pool or control. After 72 hours Pyk2 and FAK expression was detected by immunoblot with specific antibodies.
Blot is representative of three independent experiments with an average Pyk2 depletion level of 92.663 (arbitrary units) as assessed by densitometric
analysis (B and C) Migration and invasion of 5637 cells were assessed as described in Materials and Methods after 16 hours of IGF-I stimulation. Values
are expressed as fold change over SFM and represent mean 6 SD. *P,0.05; **P,0.01. (D) Pyk2-depleted 5637 cells were tested for the activation of
the Akt and MAPK pathways after 10 min of IGF-I stimulation using a mix of phospho-specific antibodies (PathScan Cocktail I). eIF4E monitors protein
loads. Blot is representative of three independent experiments.
doi:10.1371/journal.pone.0040148.g003
Pyk2 and IGF-IR in Bladder Cancer
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prevalently expressed at focal adhesions while Pyk2 expression is
more distributed throughout the cell and sometimes enriched in
perinuclear regions [29].
We have recently shown that IGF-I stimulation of invasive
urothelial cells induces paxillin phosphorylation at Tyrosine 31
[17], a process mediated by FAK in other cellular models [21]. We
further showed that paxillin localizes with FAK at the leading edge
of migrating cells [17]. Because in other tumor models FAK is
required for PI3K- and Ras-dependent tumorigenesis [30] and the
integrins/FAK complex activates Ras signaling to MAPK [31,32]
a plausible mechanism by which IGF-I promotes migration and
invasion of bladder cancer cells would be by activating FAK and
the signaling cascade leading to Akt, MAPK and paxillin
activation. Surprisingly, FAK depletion in 5637 cells had no effect
in modulating both IGF-I-induced migration and IGF-IR-de-
pendent activation of the Akt and MAPK pathways. The modest
inhibitory effect on invasion detected in FAK-depleted 5637 cells
in the absence of MAPK and Akt inhibition suggest that additional
Figure 4. Pyk2 colocalizes with the IGF-IR and complexes with IRS-2 and Grb2 after IGF-I stimulation of urothelial cancer cells. (A)
5637 cells were serum-starved over night and then treated with 50 ng/ml of IGF-I for 30 minutes. After fixation, cells were labeled with a monoclonal
anti-IGF-IR (green) and a polyclonal anti-Pyk2 (red) and imaged by confocal microscopy. The pictures of merged fields show colocalization (yellow) of
IGF-IR and Pyk2 in the IGF-I treated cells (arrows) but not in unstimulated control cells. The distinct co-localization of Pyk2 and IGF-IR is detectable in
the Z stacks (yellow staining, bottom panel). Pictures are representative of at least 10 independent fields from two independent experiments. An
average of 300 cells was examined for each condition. Bar: 10 mm. (B) 5637 and(C) T24 bladder cancer cells were serum-starved for 24 hours and then
stimulated with 50 ng/ml of IGF-I for 30 minutes. Two mg of cell lysates were immunoprecipitated with anti-Pyk2 polyclonal antibodies. IRS-1, IRS-2,
Grb2 and Pyk2 levels were assessed by immunoblot with specific polyclonal antibodies. Blots are representatives of three independent experiments.
doi:10.1371/journal.pone.0040148.g004
Pyk2 and IGF-IR in Bladder Cancer
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MAPK- and Akt-independent pathways may partially contribute
to FAK-dependent invasive signaling in these cells.
However, we discovered that altering Pyk2 expression by
transient overexpression of either wild type or dominant-negative
Pyk2 proteins, or by siRNA-mediated Pyk2 depletion, had a major
effect on IGF-I-induced motility and invasive ability of 5637 and
T24 urothelial cancer cells. These functional assays were further
corroborated by biochemical assays showing a significant in-
Figure 5. Pyk2 is up-regulated in bladder cancer tissues. (A) Pyk2 expression on a bladder cancer tissue microarray was determined by
immunofluorescence and AQUA analysis using the AQUA PM-2000 system (HistoRx, Inc). Automated quantification and statistics on the different
types of bladder cancer tumor tissues (B) and in the cytoplasmic and nuclear fractions of urothelial carcinoma cells (C) was calculated by AQUA
Software. (B) *P,0.05. **P,0.01 compared to normal tissue controls. (C) *P=0.012 compared to non-neoplastic nuclear fraction.
doi:10.1371/journal.pone.0040148.g005
Pyk2 and IGF-IR in Bladder Cancer
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hibition of IGF-IR-activation of downstream signaling when
intracellular Pyk2 levels were reduced. Thus, these results suggest
that Pyk2 may have a more prevalent role than FAK in regulating
IGF-IR-dependent biological responses in invasive urothelial
cancer cells.
As Pyk2 depletion severely inhibits IGF-I-induced signaling, it
could be argued that the effects of Pyk suppression on migration
are a consequence of reduced proliferation/survival. However, we
have previously shown that in both 5637 and T24 urothelial
cancer cells the ability of IGF-I to induce motility (migration and
invasion) is totally independent from the IGF-IR ability to sustain
proliferation/survival, as in fact IGF-I does not enhance cell
growth in these cells, which proliferate in the absence of serum
[17].
To investigate the mechanisms by which Pyk2 may regulate
IGF-I-dependent biological responses in urothelial cells, we
initially assessed by confocal microscopy whether upon IGF-I-
stimulation Pyk2 colocalized with paxillin in focal adhesions.
However, in both serum-starved and IGF-I-stimulated 5637 and
T24 cells we could not detect any colocalization of Pyk2 and
paxillin, and Pyk2 staining was more diffuse throughout the
cytoplasm and not enriched in focal adhesions (not shown). In
addition, we performed co-immunoprepitation experiments in
which we failed to detect a Pyk2/paxillin complex (not shown).
These results strongly indicate that Pyk2 action in regulating IGF-
I-dependent motility of urothelial cancer cells can be separated
from paxillin function at focal adhesions.
Ligand-dependent recruitment of IRS-1/2 and Grb2 proteins to
the IGF-IR is a critical step in the activation of the Akt and MAPK
pathways in various IGF-IR-dependent biological responses
[25,33,34,35,36]. Interestingly, IGF-I stimulation of 5637 and
T24 urothelial cancer cells evoked the formation of a complex
containing Pyk2, IRS-2 and Grb2 suggesting that in urothelial
cancer cells Pyk2 may work as a critical signaling hub downstream
of the IGF-IR. Whether Pyk2 binds directly to the IGF-IR and
mediates the recruitment of IRS-2 and Grb2 to the receptor has
not been demonstrated. So far we have not being able to detect an
interaction between the IGF-IR and Pyk2 by co-immunoprecip-
itation experiments in 5637 cells but this negative result could be
likely attributed to the relative low level of endogenous proteins.
On the other hand, this result could also indicate that the IGF-IR
and Pyk2 may interact indirectly in a complex with other signaling
molecules of the IGF-IR system, such as IRS-1 and IRS-2.
However, we have demonstrated by confocal microscopy that the
IGF-IR and Pyk2 colocalize in ligand-dependent fashion suggest-
ing that Pyk2 upon IGF-I stimulation may complex with the IGF-
IR and facilitate the recruitment of signaling molecules to the
receptor.
Recent experiments in vascular smooth muscle cells have
demonstrated that upon IGF-I stimulation Pyk2 mediates the
recruitment of Grb2 to the signaling SHP-1/SHP2/Src complex
thus promoting MAPK activation and cell proliferation [37].
However, whether a similar mechanism may be conserved in
urothelial cancer cells remains to be elucidated.
Our recent data have demonstrated that the IGF-IR is
overexpressed in invasive bladder cancer tissues compared to
normal tissue controls [17] and IGF-IR levels increase with
bladder cancer progression [18]. The AQUA analysis we
performed shows that Pyk2 expression is significantly upregulated
in various bladder cancer tissue subtypes compared to normal
controls but we could not detect a statistically significant difference
in Pyk2 expression levels associated with different stages of
urothelial carcinoma. A study with a larger sampling representing
different stages of urothelial carcinoma is required to clearly
establish whether Pyk2 may work as a prognostic marker for
bladder cancer progression. Interestingly, in urothelial carcinoma
cells the AQUA analysis revealed a statistically significant increase
in the fraction of Pyk2 detected in the nucleus compared to cells in
normal controls. Pyk2 localization in the nucleus has been
previously demonstrated [38,39] but the function of Pyk2 in the
nucleus has not been characterized. Our results provide the first
evidence of increased levels of nuclear Pyk2 in bladder cancer cells
thereby suggesting the novel hypothesis that in bladder cancer cells
IGF-I-activated Pyk2 may act not only in the cytoplasm but also
translocate into the nucleus, where it might work as a transcription
factor. Significantly, IRS-1 and IRS-2 proteins have been shown
to translocate to the nucleus in several cancer cell models
[40,41,42,43], where they regulate gene expression [43,44]. In
addition IRS-1 level in the nucleus predicts tamoxifen response in
patients with early breast cancer [45], Thus, our results suggest the
attractive hypothesis that IRS-1 or IRS-2 proteins may play a role
in regulating Pyk2 translocation and/or interact with Pyk2 in the
nucleus.
Experiments are currently under way to determine whether
Pyk2 nuclear translocation is detectable in various urothelial
cancer cell lines and is mediated by IGF-I. Future experiments will
also determine IRS-1 or IRS-2 action in regulating Pyk2 nuclear
translocation and function.
In conclusion, we have identified Pyk2 as a novel critical
regulator of IGF-IR-dependent motility and invasion of urothelial
cancer cells. These studies will greatly contribute to the
identification of novel targets for therapeutic intervention in
bladder tumors. In addition IGF-IR and Pyk2 may work as novel
biological markers for bladder cancer progression.
Materials and Methods
Cells and Materials
Urothelial carcinoma-derived human 5637 and T24 cells were
obtained from ATCC (Manassas, VA, USA. 5637 and T24 cells
were maintained in RPMI medium supplemented with 10% fetal
bovine serum (FBS). Serum-free medium (SFM) is DMEM
supplemented with 0.1% bovine serum albumin and 50 mg/mL
of transferrin (Sigma-Aldrich, St Louis, MO, USA). Recombinant
IGF-I was purchased from Calbiochem (San Diego, CA, USA).
siRNA-mediated Gene Silencing
To silence FAK or Pyk2 we used RNA interference by using
small-interfering RNA (siRNA). 5637 and T24 cells were
transfected with vehicle (DEPC-treated water), control siRNA
(scrambled), or siRNA specific oligos (200–400 pmol/L) using the
TransIT-siTKO reagent (Mirus Bio LLC, Madison, WI, USA).
Both scrambled and anti-FAK or anti-PYK2 siRNA oligos were
from Thermo Scientific Dharmacon (siGenome Smartpool
siRNA) (Lafayette, CO, USA). Cells were analyzed for motility
and signaling 72 hours post-transfection. siRNA efficiency was
detected by immunobloting using anti-FAK (#3285) and anti-
Pyk2 (#3090) polyclonal antibodies (both from Cell Signaling
Technology, Beverly, MA, USA). ß-actin was detected using anti-
ß-actin polyclonal antibody (Sigma-Aldrich). Densitometric anal-
ysis was performed using the ImageJ program (rsbweb.nih.gov/ij/
).
Transient Transfection Assays
5637 cells were transiently transfected using the TransITH-
Prostate Transfection Kit (Mirus BIO LLC) with the expression
plasmid pShCMV.3X FLAG expressing either wild type or kinase-
dead (K457A) Pyk2 mutant protein. Forty-eight hours post
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transfection, cells were serum-starved for additional 24 hours and
then stimulated or not with 50 ng/mL of IGF-I. Migration was
determined after 18 hours of incubation with the ligand, as stated
below. In parallel, cells were lysed with cold RIPA buffer and the
expression of the transfected plasmids was detected by western blot
analyses using an anti-FLAG antibody (Santa Cruz Biotechnolo-
gies, Inc.).
Migration and Invasion Assays
5637 or T24 cells were plated in duplicate at a density of 36104
cells/35-mm2 plates in serum-supplemented medium. After 24
hours, cells were transferred to SFM or SFM supplemented with
50 ng/mL of IGF-I. Migration or invasion experiments were
carried on for 4 hours or 16 hours, depending on the cell line used
(T24 or 5637, respectively). Migration experiments were per-
formed using HTS FluoroBloksTM inserts (BD, San Jose, CA,
USA) as previously described [17,18,46,47]. Membranes were
mounted on a slide and migrated cells were counted and
photographed with a Zeiss Axiovert 200 M cell live microscope
at the Kimmel Cancer Center Bioimaging Facility. Cell invasion
through a 3D-extracellular matrix was assessed using BD
MatrigelTM-coated Invasion Chambers (BD Biocoat) [17,18,47].
After 24 hours filters were washed, fixed, and stained with
Coomassie Brilliant Blue. Cells that had invaded to the lower
surface of the filter were counted under the microscope.
Analyses of Protein/Protein Interactions
5637 or T24 cells were serum-starved for 24 hours and then
stimulated with IGF-I (50 ng/mL) for 30 minutes. Cells were lysed
in cold RIPA buffer without sodium deoxycholate. The insoluble
material was separated by centrifugation and the supernatants
were incubated at 4uC under rotation for 18 hours with anti-Pyk2
polyclonal antibody (Sigma-Aldrich). At the end of the incubation,
immunocomplexes were separated by adding 30 mL of mix protein
A/G-Sepharose for additional 30 minutes. The resolved proteins
were reduced in 40 mL of Laemmli buffer and subjected to SDS-
PAGE. IRS-1 and IRS-2 interactions were determined by
immunoblot using Anti-IRS-1 and Anti-IRS-2 polyclonal anti-
bodies from Millipore (Burlington, MA, USA). The anti-Grb2
monoclonal antibody is from BD Biosciences. Blots are represen-
tative of three independent experiments.
Detection of Activated Signaling Pathways
5637 or T24 cells were serum-starved for 24 hours and then
stimulated with IGF-I (50 ng/mL) for 5, 10, 30 and 120 minutes.
Pyk2 phosphorylation was detected by immunoblot using anti-
phospho-Pyk2 (Tyr-402) antibodies (Cell Signaling Technology).
The activation of p90RSK, Akt, ERK1/2 and S6 Ribosomal
Protein was analyzed by western immunoblot using the PathScan
Multiplex Western Cocktail I (Cell Signaling Technology). ElF4E
protein is used as control to monitor the loading of the samples.
Confocal Microscopy
5637 cells were plated onto 4-well chamber slides (BD
Bioscences) and serum-starved over night prior to treatment with
50 ng/ml of IGF-I for 10, 30 and 60 minutes. Cells were then
washed with 1X PBS and fixed with 4% PFA for 30 minutes at
room temperature. Subsequently, slides were subjected to immu-
nofluorescence and confocal analysis as previously described
[18,46,48,49,50]. Primary antibodies were anti-IGF-IR mono-
clonal (Calbiochem) and anti-Pyk2 polyclonal antibodies (Santa
Cruz Biotechnologies). Secondary antibodies were goat anti-
mouse IgG Alexa FluorH 488 and goat anti-rabbit IgG Alexa
FluorH 594 antibodies (Invitrogen). Confocal analysis was
performed on a Zeiss LSM810 microscope. The filters were set
to 488 and 594 nm for dual channel imaging. All the images were
then analyzed using Image J and Adobe Photoshop CS3 (Adobe
Systems, San Jose, CA) software.
Pyk2 Expression in Bladder Cancer Tissues
Pyk2 expression levels in bladder cancer tissue were determined
by AQUA analysis (Automated Quantitative Analysis) [28] on an
Accumax bladder cancer tissue microarray (TMA #A215),
composed by 4 non neoplastic spots and 45 different bladder
cancer tissues (n = 33 urothelial carcinoma, n= 5 adenocarcinoma,
n = 4 squamous carcinoma and n= 3 urothelial carcinoma in situ,
two spots for each case). Detailed information regarding the TMA
used is available on Accumax website. The antibodies used for
immunofluorescence were rabbit pan-cytokeratin antibody (Cy2
conjugated, DAKO), Pyk2 antibody (Rabbit monoclonal YE353,
Abcam) and DAPI. Pyk2 antibody was conjugated with Cy5 since
it is outside the auto-fluorescence spectrum of tissue. Nuclear and
cytoplasmic mask were automatically defined by AQUA Software,
and applied to quantify Pyk2 expression on TMA. The analysis
was performed at the Kimmel Cancer Center Translational Core
Facility using an AQUA PM-2000 system (HistoRx, Inc).
Automated quantification and statistics was calculated by AQUA
Software. *P,0.05. **P,0.01 compared to normal.
Statistical Analysis
Experiments were carried out in triplicate and repeated at least
three times. Results are expressed as mean 6 SD. All statistical
analyses were carried out with PRISM GraphPad Software, v.5.
Results were compared using the two-sided Student’s t test.
Differences were considered statistically significant at P,0.05.
Supporting Information
Figure S1 Pyk2 is critical for IGF-IR-induced motility,
invasion and signaling of invasive urothelial cancer
cells. (A) T24 cells were transfected with the Pyk2 siGenome
pool or control. After 72 hours Pyk2 and FAK expression was
detected by immunoblot with specific antibodies. Blot is
representative of three independent experiments with an average
Pyk2 depletion level of 93.463.5 (arbitrary units) as assessed by
densitometric analysis (B and C) Migration and invasion of T24
cells were assessed as described in Materials and Methods after 4
hours of IGF-I stimulation. Values are expressed as fold change
over SFM and represent mean 6 SD. *P,0.05. (D) Pyk2-depleted
T24 cells were tested for the activation of the Akt and MAPK
pathways after 10 min of IGF-I stimulation using a mix of
phosphor-specific antibodies (Pathscan cocktail I). eIF4E monitors
protein loads. Blot is representative of three independent
experiments.
(TIF)
Figure S2 Pyk2 is up-regulated in urothelial carcinoma.
Pyk2 expression on a bladder cancer tissue microarray was
determined by immunofluorescence and AQUA analysis using the
AQUA PM-2000 system (HistoRx, Inc). Higher magnification
images from the same normal and urothelial carcinoma tissue
samples shown in Figure 5 were acquired using a LEICA
DM5500B microscope equipped with Leica Application Suite,
Advanced Fluorescence 1.8 software (Leica Mycrosystem, Inc.)
using a 63X Objective. Pictures are representative of at least 10
independent fields. Bar ,10 mm.
(TIF)
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